Actively Recruiting
Randomized, Double-Blind Trial Evaluating Daily Elamipretide Injections for Male Patients With Genetically Confirmed Barth Syndrome Assessing Efficacy and Safety Over 72 Weeks
Led by Stealth BioTherapeutics Inc. · Updated on 2026-09-17
48
Participants Needed
3
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 3b4 randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety, and pharmacokinetics of once daily subcutaneous injections of elamipretide in male patients aged 5 to 55 years with genetically confirmed Barth syndrome BTHS. The study aims to confirm the efficacy of elamipretide, already approved in the United States as FORZINITY based on improved knee extensor muscle strength, an intermediate clinical endpoint. Participants will receive once daily subcutaneous injections of either elamipretide or a matching placebo for 72 weeks. The elamipretide is provided as a sterile aqueous solution in multi-dose glass vials. The trial includes two parallel groups undergoing this treatment regimen under quadruple masking to compare outcomes between the active drug and placebo over the study period. During the study, participants will be monitored regularly with assessments including efficacy and safety evaluations at baseline and throughout the 72-week treatment period. Researchers will measure primary and multiple secondary efficacy endpoints related to muscle strength and function. Safety monitoring and adherence to study requirements will be ensured, with participation lasting for the full 72 weeks of treatment exposure.
CONDITIONS
Brief Title
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
Research Team
R
Rekha Sathyanarayana
L
Lani Glennon
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here